Novartis' Autoimmune Drug Ianalumab Succeeds in Late-Stage Trials, Poised to Become Blockbuster Therapy

Stock trading depends onGolden Qilin Analyst Report, authoritative, professional, timely, comprehensive, help you explore potential thematic opportunities!

(Source: Cailian Press)

Cailian Press, August 11 (Editor Niuzhan Lin)Swiss pharmaceutical giant Novartis announced that an experimental drug it developed succeeded in a pivotal late-stage clinical trial for treating autoimmune diseases, injecting more confidence into the company’s R&D in this field.

According to a statement released by Novartis on Monday, patients with Sjögren’s disease who received treatment with Ianalumab showed significant improvement in their condition, and both trials met their primary objectives.

It is reported that Sjögren's syndrome is a common autoimmune disease, characterized by progressive dysfunction, inflammation, and destruction of salivary and lacrimal glands, along with some extra-glandular pathological features. The disease is associated with autoreactive B cells and T cells, but its cellular immunological pathogenesis has not been fully elucidated.

Novartis stated that the drug was well-tolerated and is expected to become the first targeted treatment option for the disease. Following this news, Novartis' U.S.-listed shares rose nearly 1.7% at one point during early trading.

Ianalumab is also in development for the treatment of other autoimmune diseases, including lupus erythematosus. Novartis hopes to drive the company's performance growth through this drug. Analysts predict that by 2031, Ianalumab is expected to become a "blockbuster" product with annual sales exceeding $1 billion. Meanwhile, competitors, including Sanofi and Roche, are also developing therapies targeting these diseases.

Facing the Impact of Generic Drugs on Three Core Drugs (Including the Best-Selling Heart Failure Drug Entresto) This Year, Novartis Is Accelerating the Expansion of Its Innovative Drug Pipeline. Once a pharmaceutical group covering various businesses such as ophthalmology and generics, Novartis is now focusing on innovative drug research and development under the leadership of CEO Vas Narasimhan.

Novartis' Head of Development and Chief Medical Officer, Shreeram Aradhye, stated in a declaration that the company plans to discuss the clinical trial results with health regulatory authorities. The drug has received Fast Track designation from the U.S. Food and Drug Administration (FDA), and Novartis intends to submit it for approval to health authorities around the world.

Novartis pointed out that Sjögren's syndrome is one of the most common rheumatic autoimmune diseases, which can lead to inflammation and tissue damage, significantly impacting patients' daily lives. Currently, treatment options are very limited, indicating a clear unmet medical need.

Analysts say that Ianalumab has significant growth potential in the coming years. The drug originated from an early collaboration project between Novartis and Germany's MorphoSys, which was acquired by Novartis last year.